Pharmaceuticals, Biotechnology and Life Sciences
Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.
— Filgotinib 200 mg Demonstrated Greater Efficacy Compared with Placebo in the Induction and Maintenance of Remission in the SELECTION…
Takeda’s approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease.
BARCELONA, Spain–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of…
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.
Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only…
The U.S. Food and Drug Administration today expanded the approval of Pfizer’s Xeljanz (tofacitinib), the first oral medication approved for…
TiGenix has entered into a partnerships with the largest patient advocacy groups focused on Crohn’s disease and ulcerative colitis in the United States (US) and Europe.